Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ISN-001 by Anterogen for Epidermolysis Bullosa: Likelihood of Approval
ISN-001 is under clinical development by Anterogen and currently in Phase II for Epidermolysis Bullosa. According to GlobalData, Phase II...
ISN-001 by Anterogen for Burns: Likelihood of Approval
ISN-001 is under clinical development by Anterogen and currently in Phase II for Burns. According to GlobalData, Phase II drugs...
ISN-001 by Anterogen for Crohn's Disease (Regional Enteritis): Likelihood of Approval
ISN-001 is under clinical development by Anterogen and currently in Phase I for Crohn's Disease (Regional Enteritis). According to GlobalData,...